Sequential taxane and anthracycline-containing neoadjuvant regimens: The sequential order impact

Breast

Volumn 20, Issue 1, 2011, Pages 46-49

  Thiery Vuillemin, A ^a,b   Llombart Cussac, A ^e   Chaigneau, L ^a   Villanueva, C ^a   Bazan, F ^a   Montcuquet, P ^c   Maisonnette Escot, Y ^a   Sautiere, J L ^d   Algros, M P ^d   Pivot, X ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b INSERM   (France)

^c Saint Vincent Private Hospital   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Anthracycline; Breast cancer; Neoadjuvant; Taxane; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CENTER; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT RESPONSE;

EID: 79451473947     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.07.001     Document Type: Article

References (30)

1. Schwartz G.F., Birchansky C.A., Komarnicky L.T., Mansfield C.M., Cantor R.I., Biermann W.A., et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994, 73:362-369.
2. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst 1990, 82:1539-1545.
3. Jacquillat C., Weill M., Baillet F., Borel C., Auclerc G., de Maublanc M.A., et al. Results of neo-adjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990, 66:119-129.
4. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al. Effect of preoperative chemotherapy on outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
5. Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R.G., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
6. Makris A., Powles T.J., Ashley S.E., Chang J., Hickish T., Tidy V.A., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998, 9:1179-1184.
7. van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19:4224-4237.
8. Mauriac L., MacGrogan G., Avril A., Durand M., Floquet A., Debled M., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999, 10:47-52.
9. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006 Apr 20, 24(12):1940-1949. Erratum in: J Clin Oncol 2006 Jul 1;24(19):3221.
10. Rouzier R., Extra J.M., Klijanienko J., Falcou M.C., Asselain B., Vincent-Salomon A., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002, 20:1304-1310.
11. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
12. Hutcheon A.W., Heys S.D., Sarkar T.K., Ogston K.N., Miller I.D., Payne S., et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 2003, 82:S9.
13. Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999, 17:3412-3417.
14. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al. The effect on tumor responseof adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174.
15. Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., Blum R.H. Primary systemic therapy of breast cancer. Oncologist 2006 Jun, 11(6):574-589.
16. ®) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br J Cancer 2002, 86:692-697.
17. AJCC Cancer staging manual 2002, Springer. 7th ed.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
19. Pivot X., Thierry-Vuillemin A., Villanueva C., Bazan F. Response rates: a valuable signal of promising activity?. Cancer J 2009, 15:361-365.
20. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
21. Common Terminology Criteria for Adverse Events v2.0 http://ctep.cancer.gov/reporting/ctc.html.
22. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Clinical course of breast cancer. J Am Stat Assoc 1958, 185:1457-1481.
23. Cox D.R. Regression models and life tables. JR Stat Soc B 1972, 34:187-202.
24. Piedbois P., Serin D., Priou F., Laplaige P., Greget S., Angellier E., et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007, 18:52-57.
25. Puhalla S., Mrozek E., Young D., Ottman S., McVey A., Kendra K., et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 2008, 26:1691-1697.
26. Earl H.M., Vallier A., Hiller L., Fenwick N., Iddawela M., Hughes-Davies L., et al. Neo-Tango: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): fi rst report of the primary endpoint, pathological complete response (pCR). Proc Am Soc Clin Oncol 2009, 27. (suppl): abstr 522.
27. Miller K.D., Soule S.E., Calley C., Emerson R.E., Hutchins G.D., Kopecky K., et al. Randomized phase II trial of the antiangiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005, 89:187-197.
28. Coudert B.P., Largillier R., Arnould L., Chollet P., Campone M., Coeffic D., et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007 Jul 1, 25(19):2678-2684. Epub 2007 May 21. Erratum in: J Clin Oncol 2007 Nov 1;25(31):5048.
29. Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007 Jan 1, 13(1):228-233.
30. Gianni L., Eiermann W., Semiglazov V., Manikhas G.M., Lluch A., Tjulandin S., et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Proceedings SABCS. Cancer Res 2009.